Oxidative stress: The old enemy in Alzheimer's disease pathophysiology

Current Alzheimer Research

Volumn 2, Issue 4, 2005, Pages 403-408

  Moreira, Paula I ^a,b   Honda, Kazuhiro ^a   Liu, Quan ^a   Santos, Maria S ^b   Oliveira, Catarina R ^b   Aliev, Gjumrakch ^a   Nunomura, Akihiko ^c   Zhu, Xiongwei ^a   Smith, Mark A ^a   Perry, George ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

; Alzheimer disease; Amyloid ; Metal; Mitochondria; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; ARGININE; CALCINEURIN; CITRULLINE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN PEROXIDE; HYDROXYL GROUP; LIPOPROTEIN; MEMBRANE LIPID; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE SYNTHASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; TAU PROTEIN; TRANSITION ELEMENT;

ALZHEIMER DISEASE; DISEASE COURSE; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; HUMAN; MITOCHONDRION; NERVE CELL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; HUMANS; METALS; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 24644443839     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720505774330537     Document Type: Review

References (74)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschr Psychiatr 64: 146-148 (1907).
2. Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol Med 7: 645-651 (1989).
3. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767 (2001).
4. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59: 1011-1017 (2000).
5. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19: 1959-1964 (1999).
6. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, et al. Oxidative damage in Alzheimer's. Nature 382: 120-121 (1996).
7. Smith MA, Richey Harris PL, Sayre LM, Beckman JS and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657 (1997).
8. Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P and Perry G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol (Berl) 89: 291-295 (1995).
9. Smith MA. Alzheimer disease. Int Rev Neurobiol 42: 1-54 (1998).
10. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG and Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68: 2092-2097 (1997).
11. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA and Perry G. Oxidative stress signalling in Alzheimer's disease. Brain Res 1000: 32-39 (2004).
12. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91: 5710-5714 (1994).
13. Smith MA, Rudnicka-Nawrot M, Richey PL, Praprotnik D, Mulvihill P, Miller CA, et al. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 64: 2660-2666 (1995).
14. Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N, Vitek MP, et al. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 31: 175-180 (2001).
15. Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, et al. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 133: 507-513 (2002).
16. Wallace DC. Mitochondrial diseases in man and mouse. Science 283: 1482-1488 (1999).
17. Smith MA, Harris PL, Sayre LM and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94: 9866-9868 (1997).
18. Ferri KF and Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3: E255-263 (2001).
19. Pereira C, Ferreiro E, Cardoso SM and de Oliveira CR. Cell degeneration induced by amyloid-beta peptides: implications for Alzheimer's disease. J Mol Neurosci 23: 97-104 (2004).
20. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023 (2001).
21. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70: 357-360 (2002).
22. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 162: 1623-1627 (2003).
23. Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, et al. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res 25: 665-674 (2003).
24. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci 977: 45-64 (2002).
25. Connor JR, Milward EA, Moalem S, Sampietro M, Boyer P, Percy ME, et al. Is hemochromatosis a risk factor for Alzheimer's disease? J Alzheimers Dis 3: 471-477 (2001).
26. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL and Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52 (1998).
27. Atwood CS, Huang X, Moir RD, Tanzi RE and Bush AI. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met Ions Biol Syst 36: 309-364 (1999).
28. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277: 45518-45528 (2002).
29. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145: 42-47 (1994).
30. Premkumar DR, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, et al. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 65: 1399-1402 (1995).
31. Keyse SM and Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 86: 99-103 (1989).
32. Honda K, Casadesus G, Petersen RB, Perry G and Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci USA 1012: 179-182 (2004).
33. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616 (1999).
34. Finefrock AE, Bush AI and Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 51: 1143-1148 (2003).
35. Bayer TA, Schafer S, Simons A, Kemmling A, Kamer T, Tepest R, et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci USA 100: 14187-14192 (2003).
36. Sparks DL and Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 100: 11065-11069 (2003).
37. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA and Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74: 270-279 (2000).
38. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359: 325-327 (1992).
39. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron 37: 925-937 (2003).
40. Ramsden M, Plant LD, Webster NJ, Vaughan PF, Henderson Z and Pearson HA. Differential effects of unaggregated and aggregated amyloid beta protein (1-40) on K(+) channel currents in primary cultures of rat cerebellar granule and cortical neurones. J Neurochem 79: 699-712 (2001).
41. Ramsden M, Henderson Z and Pearson HA. Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status. Brain Res 956: 254-261 (2002).
42. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 893: 362-364 (1999).
43. Smith MA, Nunomura A, Zhu X, Takeda A and Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2: 413-420 (2000).
44. Unnikrishnan MK and Rao MN. Antiinflammatory activity of methionine, methionine sulfoxide and methionine sulfone. Agents Actions 31: 110-112 (1990).
45. Hiller KO and Asmus KD. Tl2+ and Ag2+ metal-ion-induced oxidation of methionine in aqueous solution. A pulse radiolysis study. Int J Radiat Biol Relat Stud Phys Chem Med 40: 597-604 (1981).
46. Varadarajan S, Yatin S, Aksenova M and Butterfield DA. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130: 184-208 (2000).
47. Kontush A, Berndt C, Weber W, Akopyan V, Arlt S, Schippling S, et al. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 30: 119-128 (2001).
48. Behl C, Davis JB, Lesley R and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827 (1994).
49. Mark RJ, Lovell MA, Markesbery WR, Uchida K and Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68: 255-264 (1997).
50. Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 21: RC118 (2001).
51. Mark RJ, Pang Z, Geddes JW, Uchida K and Mattson MP. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 17: 1046-1054 (1997).
52. Iversen LL, Mortishire-Smith RJ, Pollack SJ and Shearman MS. The toxicity in vitro of beta-amyloid protein. Biochem J 311 (Pt 1): 1-16 (1995).
53. Kontush A. Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 31: 1120-1131 (2001).
54. Schubert D and Chevion M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 216: 702-707 (1995).
55. Bondy SC, Guo-Ross SX and Truong AT. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res 799: 91-96 (1998).
56. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30: 447-450 (2001).
57. Walter MF, Mason PE and Mason RP. Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. Biochem Biophys Res Commun 233: 760-764 (1997).
58. Butterfield DA and Bush AI. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25: 563-568 (2004).
59. Soriani M, Pietraforte D and Minetti M. Antioxidant potential of anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 312: 180-188 (1994).
60. Lynch SM and Frei B. Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. Biochim Biophys Acta 1345: 215-221 (1997).
61. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A and Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-130 (2000).
62. Brandt R, Leger J and Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 131: 1327-1340 (1995).
63. Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 274: 25490-25498 (1999).
64. Hamdane M, Delobel P, Sambo AV, Smet C, Begard S, Violleau A, et al. Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem Pharmacol 66: 1619-1625 (2003).
65. Garcia ML and Cleveland DW. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol 13: 41-48 (2001).
66. Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, et al. Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 81-88 (2001).
67. Geschwind DH. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 40: 457-460 (2003).
68. Takeda A, Smith MA, Avila J, Nunomura A, Siedlak SL, Zhu X, et al. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem 75: 1234-1241 (2000).
69. Morsch R, Simon W and Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58: 188-197 (1999).
70. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 277: 4644-4648 (2002).
71. Takeda A, Perry G, Abraham NG, Dwyer BE, Kutty RK, Laitinen JT, et al. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J Biol Chem 275: 5395-5399 (2000).
72. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G and Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59: 880-888 (2000).
73. Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, et al. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 79: 311-318 (2001).
74. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76: 435-441 (2001).